EA201000076A1 - Новые конструкты для экспрессии вируса гриппа - Google Patents

Новые конструкты для экспрессии вируса гриппа

Info

Publication number
EA201000076A1
EA201000076A1 EA201000076A EA201000076A EA201000076A1 EA 201000076 A1 EA201000076 A1 EA 201000076A1 EA 201000076 A EA201000076 A EA 201000076A EA 201000076 A EA201000076 A EA 201000076A EA 201000076 A1 EA201000076 A1 EA 201000076A1
Authority
EA
Eurasian Patent Office
Prior art keywords
expression
rna
promoter
flu virus
new structures
Prior art date
Application number
EA201000076A
Other languages
English (en)
Other versions
EA017456B1 (ru
Inventor
Маркус Волшек
Андрей Егоров
Михаэль Бергманн
Томас Мустер
Христиан Киттель
Original Assignee
Авир Грин Хилз Байотекнолоджи Рисерч Дивелопмент Трейд Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авир Грин Хилз Байотекнолоджи Рисерч Дивелопмент Трейд Аг filed Critical Авир Грин Хилз Байотекнолоджи Рисерч Дивелопмент Трейд Аг
Publication of EA201000076A1 publication Critical patent/EA201000076A1/ru
Publication of EA017456B1 publication Critical patent/EA017456B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение представляет линейный экспрессирующий конструкт, не содержащий никаких последовательностей для амплификации и/или селекции, который содержит промотор РНК-полимеразы I (polI) и сигнал терминации polI, вставленные между промотором РНК-полимеразы II (polII) и сигналом полиаденилирования, пригодный для экспрессии сегментов вирусной РНК, предпочтительно РНК вирусов гриппа. Патентоспособный конструкт полезен для эффективного и быстрого получения вирусных частиц, особенно для получения рецептур вакцин для лечения эпидемических и/или пандемических заболеваний.
EA201000076A 2007-06-27 2008-06-26 Новые конструкты для экспрессии вируса гриппа EA017456B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94665107P 2007-06-27 2007-06-27
EP07450177A EP2045323A1 (en) 2007-10-05 2007-10-05 Linear expression constructs for production of influenza virus particles
PCT/EP2008/058182 WO2009000891A2 (en) 2007-06-27 2008-06-26 Linear expression constructs for production of influenza virus particles

Publications (2)

Publication Number Publication Date
EA201000076A1 true EA201000076A1 (ru) 2010-06-30
EA017456B1 EA017456B1 (ru) 2012-12-28

Family

ID=39099653

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000076A EA017456B1 (ru) 2007-06-27 2008-06-26 Новые конструкты для экспрессии вируса гриппа

Country Status (9)

Country Link
US (1) US20100129399A1 (ru)
EP (2) EP2045323A1 (ru)
CN (1) CN101952427A (ru)
AU (1) AU2008267180B2 (ru)
CA (1) CA2689569C (ru)
EA (1) EA017456B1 (ru)
IN (1) IN2009KN04355A (ru)
NZ (1) NZ582102A (ru)
WO (1) WO2009000891A2 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9091510B2 (en) 2007-03-21 2015-07-28 Schott Corporation Transparent armor system and method of manufacture
EP2072058A1 (en) 2007-12-21 2009-06-24 Avir Green Hills Biotechnology Research Development Trade Ag Modified influenza virus
EP2233568A1 (en) * 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Novel method for generation of RNA virus
KR101800245B1 (ko) 2009-05-21 2017-11-22 노파르티스 아게 비-내인성 ｐｏｌ ｉ 프로모터를 사용하는 역 유전학
CN102666860B (zh) 2009-07-31 2015-06-17 诺华股份有限公司 反向遗传***
PL2491117T3 (pl) 2009-10-20 2014-05-30 Novartis Ag Udoskonalone sposoby odzyskiwania wirusa wykorzystujące odwrotną genetykę
EA201201620A1 (ru) * 2010-06-02 2013-07-30 Авир Грин Хилз Байотекнолоджи Рисерч Дивелопмент Трейд Аг Способ получения рнк-вируса
CN102495208B (zh) * 2011-10-24 2014-03-26 山东省农业科学院畜牧兽医研究所 禽流感病毒rt-pcr elisa试剂盒
CN104168912B (zh) * 2011-11-10 2016-08-24 北京艾棣维欣生物技术有限公司 促进剂-dna组合疫苗
EP2820126B1 (en) 2012-03-02 2017-05-17 Seqirus UK Limited Influenza virus reassortment
BR112015012380A2 (pt) 2012-12-03 2017-09-12 Novartis Ag vírus influenza recombinante
AU2014229255B2 (en) 2013-03-13 2018-12-13 Novartis Ag Influenza B virus reassortment
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
EP3004332A2 (en) 2013-06-06 2016-04-13 Novartis AG Influenza virus reassortment
WO2016207853A2 (en) 2015-06-26 2016-12-29 Seqirus UK Limited Antigenically matched influenza vaccines
WO2017005880A1 (en) 2015-07-07 2017-01-12 Seqirus UK Limited Influenza potency assays
MX2022006005A (es) 2019-11-18 2022-10-27 Seqirus Pty Ltd Metodo para producir virus de la influenza reagrupados.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU771110B2 (en) * 1998-06-12 2004-03-11 Mount Sinai School Of Medicine Of The City University Of New York, The Novel methods and interferon deficient substrates for the propagation of viruses
DE69937999T2 (de) * 1998-06-12 2009-01-29 Avir Green Hills Biotechnology Research Development Trade Ag Interferon induzierende genetisch veränderte attenuierte viren
JP2002539800A (ja) * 1999-03-24 2002-11-26 ジーン セラピー システムズ インコーポレーテッド 転写活性のあるｄｎａ断片を製造する方法
DK1185615T3 (da) * 1999-04-06 2007-11-05 Wisconsin Alumni Res Found Rekombinante influenzavirus til vacciner og genterapi
DE122007000070I1 (de) * 1999-07-14 2008-01-31 Sinai School Medicine In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren
WO2001083794A2 (en) * 2000-04-28 2001-11-08 St. Jude Children's Research Hospital Dna transfection system for the generation of infectious influenza virus
AU2003231083A1 (en) * 2002-04-26 2003-11-10 Medimmune, Llc Multi plasmid system for the production of influenza virus
DE602004027537D1 (ru) * 2003-12-23 2010-07-15 Medimmune Inc
CA2610632C (en) * 2004-06-01 2022-10-04 Mount Sinai School Of Medicine Of New York University Genetically engineered swine influenza virus and uses thereof
MX2007005818A (es) * 2004-11-19 2007-07-20 Wisconsin Alumni Res Found Vectores recombinantes de la influenza con unidades de transcripcion en tandem.
US8043856B2 (en) * 2007-06-14 2011-10-25 Wisconsin Alumni Research Foundation Adenoviral vectors for influenza virus production

Also Published As

Publication number Publication date
IN2009KN04355A (ru) 2015-07-10
EP2160462A2 (en) 2010-03-10
CA2689569C (en) 2020-10-27
AU2008267180B2 (en) 2014-07-10
CA2689569A1 (en) 2008-12-31
WO2009000891A3 (en) 2009-02-26
EA017456B1 (ru) 2012-12-28
WO2009000891A2 (en) 2008-12-31
NZ582102A (en) 2012-06-29
AU2008267180A1 (en) 2008-12-31
EP2045323A1 (en) 2009-04-08
EP2160462B1 (en) 2017-07-26
US20100129399A1 (en) 2010-05-27
CN101952427A (zh) 2011-01-19

Similar Documents

Publication Publication Date Title
EA201000076A1 (ru) Новые конструкты для экспрессии вируса гриппа
EA200501890A1 (ru) Вирусы гриппа высокого титра для приготовления вакцин и генной терапии
EA200970013A1 (ru) Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы
IL186611A0 (en) Vaccine against pandemic strains of influenza viruses
WO2007047831A3 (en) Functional influenza virus like particles (vlps)
UY34983A (es) Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv") y c omposiciones relacionadas
EA201590384A1 (ru) 6-аминокислота-гетероарилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в
EA201891712A3 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
EA201001045A1 (ru) Модифицированный вирус гриппа
WO2009143524A3 (en) Nanoemulsion vaccines
MX2008006851A (es) Materiales y metodos para tratar infecciones virales con un compuesto de cisteamina.
EA201290897A1 (ru) Вакцины для пандемического гриппа
AU2012332832A8 (en) Compositions useful for the treatment of viral diseases
EA201390806A1 (ru) Конструкция пептидного каркаса
EA202190602A2 (ru) 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
CL2008003819A1 (es) Compuestos derivados del acido 2-cetoamino benzoico sustituido, inhibidores del virus de la hepatitis c; composicion farmaceutica; y su uso en el tratamiento de una infeccion por vhc.
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
EA201000277A1 (ru) Соединения для лечения гепатита с
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
EA201171370A1 (ru) Универсальные способы определения вирусов гриппа
BR112017006680A2 (pt) variantes de vírus influenza a
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
DE602005027872D1 (de) Virosomenpartikel mit antigenen aus influenzavirus und hepatitis-b-virus

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU